Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: Thermo Finnigan, MDS Proteomics Will Jointly Develop FTMS Proteomics System

NEW YORK, May 9-Equipment manufacturer Thermo Finnigan and MDS Proteomics said today that they plan to work together to adapt mass spectrometry devices for the analysis of low-abundancy proteins.


The two companies will customize Thermo's Fourier transform ion cyclotron resonance mass spectrometry technology for use in identifying disease-specific proteins that may be present only in trace amounts.


MDS Proteomics will provide technical specifications, evalute and assess the equipment, and provide proteomics-specific expertise to guide instrument development. Thermo Finnigan will give MDS Proteomics exclusive beta-version access to the machines as they progress.


Thermo Finnigan will use this feedback in developing a commercial FTMS-based proteomics system that offers high dynamic range, ultra-high sensitivity and peptide sequencing capabilities in order to speed and improve detection of low-level proteins.


The company says that FTMS technology allows for a several thousand-fold boost in mass spectromic resolution and a 100-fold improvement in dynamic range detection of trace proteins.


Thermo Finnigan, a division of Thermo Electron, is based in San Jose, Calif.


MDS Proteomics is headquartered in Toronto.



The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.